Evidence Hub

Phosphodiesterase type 5 inhibitor use and hearing impairment

G. Mcgwin

Archives of Otolaryngology - Head and Neck Surgery, 2010

217,013 participants · 44 citations

Abstract

OBJECTIVE: To compare use of phosphodiesterase type 5 inhibitors (PDE-5i) between participants with and without self-reported hearing impairment using logistic regression, with and without adjustment for potentially confounding sociodemographic, behavioral, and health-related characteristics.

DESIGN: Cross-sectional.

SETTING: United States.

PATIENTS: A population-based sample of 11 525 men 40 years or older (248,217,013 weighted men) in the United States, selected from the Medical Expenditure Panel Survey (2003-2006).

MAIN OUTCOME MEASURE: Self-reported hearing impairment.

RESULTS: The overall prevalence of self-reported hearing impairment and PDE-5i use in each group was 17.9% and 2%, respectively. Men who reported hearing impairment were more likely to have also reported the use of any PDE-5i (odds ratio [OR], 2.23; 95% confidence interval [CI], 1.36-3.66). However, this association was limited to sildenafil (Viagra) (OR, 2.05; 95% CI, 1.23-3.43); no significant associations were observed for tadalafil (Cialis) or vardenafil (Levitra) (ORs, 1.40 [95% CI, 0.49-4.04] and 0.88 [95% CI, 0.35-2.22], respectively).

CONCLUSIONS: Current warnings regarding the risk of hearing loss related to PDE-5i use seems to be justified. However, the cross-sectional nature of the current study provides only limited insight regarding this relationship, and thus additional research is warranted.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free